• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床因素预测食管癌患者同步放化疗反应和生存的情况。

Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients.

机构信息

Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.

Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

出版信息

Gut Liver. 2020 Jul 15;14(4):450-458. doi: 10.5009/gnl19165.

DOI:10.5009/gnl19165
PMID:32000467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7366147/
Abstract

BACKGROUND/AIMS: Several clinical factors have been used to predict the response for concurrent chemoradiotherapy (CCRT); however, these factors are insufficient for prognostic predictions. We investigated clinical factors to assess whether they could be used to predict the response to CCRT and the survival of patients with esophageal cancer.

METHODS

Patients with esophageal cancer underwent CCRT from January 2005 to December 2015. Response to CCRT was classified as progressive disease (PD), stationary disease (SD), partial remission (PR), or complete remission (CR). Factors to predict the response to CCRT and patient survival were subsequently investigated.

RESULTS

A total of 535 esophageal cancer patients underwent CCRT. Four hundred ninety-three patients were followed up, and patient outcomes were investigated. In the adjusted analysis, patients with advanced stage disease (relative risk [RR], 0.28 in stage III and 0.12 in stage IV compared to stage I), poor performance status, circumferential involvement (RR, 0.61), and male sex (RR, 0.31) were less likely to achieve CR. Advanced stage disease (hazard ratio [HR], 1.71 in stage III/IV), poor CCRT response (HR, 2.82 in PR, 4.47 in SD, 4.77 in PD compared to CR), and poor performance status (HR, 1.38 in ECOG 2-4) were found to increase mortality.

CONCLUSIONS

Advanced stage disease, poor performance status, male sex, and circumferential involvement were independent predictive factors for a poor response to CCRT. Advanced stage, poor performance status, and poor CCRT response were independent factors for decreased survival.

摘要

背景/目的:有几种临床因素已被用于预测同步放化疗(CCRT)的反应;然而,这些因素不足以进行预后预测。我们研究了临床因素,以评估它们是否可用于预测食管癌患者对 CCRT 的反应和生存。

方法

2005 年 1 月至 2015 年 12 月期间,患有食管癌的患者接受了 CCRT。将 CCRT 的反应分为进展性疾病(PD)、稳定疾病(SD)、部分缓解(PR)或完全缓解(CR)。随后,研究了预测 CCRT 反应和患者生存的因素。

结果

共有 535 例食管癌患者接受了 CCRT。493 例患者接受了随访,并对患者的结局进行了研究。在调整分析中,疾病分期较晚的患者(RR,III 期为 0.28,IV 期为 0.12,与 I 期相比)、体能状态较差、环形侵犯(RR,0.61)和男性(RR,0.31)较不易达到 CR。晚期疾病(HR,III/IV 期为 1.71)、CCRT 反应不良(HR,PR 为 2.82,SD 为 4.47,PD 为 4.77,与 CR 相比)和体能状态较差(HR,ECOG 2-4 为 1.38)被发现会增加死亡率。

结论

晚期疾病、体能状态差、男性和环形侵犯是 CCRT 反应不良的独立预测因素。晚期疾病、体能状态差和 CCRT 反应不良是降低生存率的独立因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dfe/7366147/0a8399407c5e/GNL-14-450-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dfe/7366147/3328dddfd2a9/GNL-14-450-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dfe/7366147/0a8399407c5e/GNL-14-450-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dfe/7366147/3328dddfd2a9/GNL-14-450-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dfe/7366147/0a8399407c5e/GNL-14-450-f2.jpg

相似文献

1
Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients.临床因素预测食管癌患者同步放化疗反应和生存的情况。
Gut Liver. 2020 Jul 15;14(4):450-458. doi: 10.5009/gnl19165.
2
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.老年食管癌患者放疗联合厄洛替尼与同步放化疗的比较研究:倾向评分匹配分析
Dis Esophagus. 2017 Sep 1;30(9):1-10. doi: 10.1093/dote/dox060.
3
Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.采用调强放射治疗技术对胸段食管鳞状细胞癌患者进行根治性放疗或同步放化疗后行食管切除术的疗效。
Cancer. 2017 Jun 1;123(11):2043-2053. doi: 10.1002/cncr.30565. Epub 2017 Feb 2.
4
The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma.阿帕替尼联合同步放化疗治疗不可手术切除的局部晚期食管鳞状细胞癌患者的安全性和有效性
Med Sci Monit. 2020 Nov 27;26:e927221. doi: 10.12659/MSM.927221.
5
Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.胸段食管鳞癌三模态治疗或根治性同步放化疗的价值与应用。
Cancer. 2017 Oct 15;123(20):3904-3915. doi: 10.1002/cncr.30823. Epub 2017 Jun 13.
6
Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.基于剂量递增调强放疗的同步放化疗对晚期胸段食管鳞状细胞癌有效。
Radiother Oncol. 2017 Oct;125(1):73-79. doi: 10.1016/j.radonc.2017.08.025. Epub 2017 Sep 17.
7
Local control may be the key in improving treatment outcomes of esophageal squamous cell carcinoma undergoing concurrent chemoradiation.局部控制可能是改善接受同步放化疗的食管鳞状细胞癌治疗效果的关键。
Digestion. 2014;90(4):254-60. doi: 10.1159/000368983. Epub 2014 Dec 19.
8
Prognostic value of complete response in patients with muscle-invasive bladder cancer undergoing concurrent chemoradiotherapy.肌层浸润性膀胱癌患者同步放化疗后完全缓解的预后价值。
Anticancer Res. 2013 Jun;33(6):2605-10.
9
Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation.经微探头超声评估的肿瘤长度可预测接受同步放化疗的伴有狭窄的晚期食管鳞癌患者的生存情况。
Dis Esophagus. 2011 Nov;24(8):590-5. doi: 10.1111/j.1442-2050.2011.01195.x. Epub 2011 May 3.
10
With or without consolidation chemotherapy using cisplatin/5-FU after concurrent chemoradiotherapy in stage II-III squamous cell carcinoma of the esophagus: A propensity score-matched analysis.同步放化疗后序贯顺铂/5-FU 巩固化疗与单纯同步放化疗治疗 II-III 期食管鳞癌的倾向性评分匹配分析。
Radiother Oncol. 2018 Oct;129(1):154-160. doi: 10.1016/j.radonc.2017.10.031. Epub 2017 Nov 6.

引用本文的文献

1
Simultaneous concurrent chemoradiotherapy and esophagectomy for synchronous head and neck and esophageal squamous cell carcinoma: a retrospective review.同步放化疗与食管切除术治疗同步性头颈部和食管鳞状细胞癌:一项回顾性研究。
Radiat Oncol. 2025 Jul 9;20(1):107. doi: 10.1186/s13014-025-02681-0.
2
Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.基于光谱CT的列线图用于评估食管鳞状细胞癌新辅助化疗反应
Eur Radiol. 2024 Dec 27. doi: 10.1007/s00330-024-11294-2.
3
Nomogram for predicting pathologic complete response following preoperative chemoradiotherapy in patients with esophageal squamous cell carcinoma.

本文引用的文献

1
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
2
Esophageal luminal stenosis is an independent prognostic factor in esophageal squamous cell carcinoma.食管腔狭窄是食管鳞状细胞癌的一个独立预后因素。
Oncotarget. 2017 Jun 27;8(26):43397-43405. doi: 10.18632/oncotarget.14762.
3
Cancer statistics, 2016.
预测食管鳞状细胞癌患者术前放化疗后病理完全缓解的列线图
Gastroenterol Rep (Oxf). 2024 Jul 6;12:goae060. doi: 10.1093/gastro/goae060. eCollection 2024.
4
The relationship between the treatment course and prognosis of oligometastasis after esophageal squamous cell carcinoma resection.食管癌切除术后寡转移的治疗过程与预后的关系。
Surg Today. 2024 Aug;54(8):927-934. doi: 10.1007/s00595-024-02803-3. Epub 2024 Apr 7.
5
Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda.乌干达食管癌患者的临床病理特征及治疗结果
Ecancermedicalscience. 2023 Jul 19;17:1576. doi: 10.3332/ecancer.2023.1576. eCollection 2023.
6
Elevated Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio after First Cycle of Chemotherapy and Better Survival in Esophageal Cancer Patients Receiving Concurrent Chemoradiotherapy.化疗第一周期后血小板与淋巴细胞比值和中性粒细胞与淋巴细胞比值升高与食管癌患者同步放化疗后生存改善相关。
Curr Oncol. 2022 Nov 17;29(11):8825-8834. doi: 10.3390/curroncol29110694.
7
The association between mortality and use of Chinese herbal medicine among incident stage IV esophageal cancer patients: A retrospective cohort study with core herbs exploration.IV期食管癌初诊患者死亡率与中药使用之间的关联:一项探索核心草药的回顾性队列研究
Front Pharmacol. 2022 Oct 6;13:1018281. doi: 10.3389/fphar.2022.1018281. eCollection 2022.
癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
4
Evaluation of the Glasgow Prognostic Score in patients receiving chemoradiotherapy for stage III and IV esophageal cancer.对接受放化疗的Ⅲ期和Ⅳ期食管癌患者的格拉斯哥预后评分评估。
Dis Esophagus. 2016 Nov;29(8):1071-1080. doi: 10.1111/dote.12420. Epub 2015 Oct 15.
5
MiRNA Expression Analysis of Pretreatment Biopsies Predicts the Pathological Response of Esophageal Squamous Cell Carcinomas to Neoadjuvant Chemoradiotherapy.治疗前活检组织的miRNA表达分析可预测食管鳞状细胞癌对新辅助放化疗的病理反应。
Ann Surg. 2016 May;263(5):942-8. doi: 10.1097/SLA.0000000000001489.
6
A Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer.晚期食管癌同步放化疗的荟萃分析
PLoS One. 2015 Jun 5;10(6):e0128616. doi: 10.1371/journal.pone.0128616. eCollection 2015.
7
A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma.经验证的 miRNA 谱可预测食管腺癌的治疗反应。
Cancer. 2014 Dec 1;120(23):3635-41. doi: 10.1002/cncr.28911. Epub 2014 Aug 4.
8
Gene expression analysis of pretreatment biopsies predicts the pathological response of esophageal squamous cell carcinomas to neo-chemoradiotherapy.治疗前活检的基因表达分析可预测食管鳞癌对新辅助放化疗的病理反应。
Ann Oncol. 2014 Sep;25(9):1769-1774. doi: 10.1093/annonc/mdu201. Epub 2014 Jun 6.
9
ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients.醛脱氢酶-1(ALDH-1)表达水平可预测可切除食管癌患者对术前放化疗的反应或耐药性。
Mol Oncol. 2014 Feb;8(1):142-9. doi: 10.1016/j.molonc.2013.10.007. Epub 2013 Oct 28.
10
Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer.局部晚期食管癌根治性放化疗后与局部区域失败相关的因素。
Ann Surg Oncol. 2014 Jan;21(1):306-14. doi: 10.1245/s10434-013-3303-0. Epub 2013 Nov 7.